Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer. 2012 Dec;43(4):612-8.
Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncol Rep. 2012 May;27(5):1400-6.
Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU international. 2011 Jan;107(1):58-62.
Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F, Oblaczynski M, Berberian R, Chen DY, Greenberg RE, Uzzo RG, Boorjian SA. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology. 2011 Jan;77(1):160-5.   PMCID: publisher will deposit
Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54.   PMCID: PMC3026871
Hensley HH, Hannoun-Levi JM, Hachem P, Mu Z, Stoyanova R, Khor LY, Agrawal S, Pollack A. PKA knockdown enhances cell killing in response to radiation and androgen deprivation. International journal of cancer. 2011 Feb 15;128(4):962-73.   PMCID: NIHMS236076
Ma CM, Li J. Dose specification for radiation therapy: dose to water or dose to medium?. Phys Med Biol. 2011 May 21;56(10):3073-89.   PMCID: not NIH funded
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. Int J Radiat Oncol Biol Phys. 2011 Jan;79(1):65-70.   PMCID: PMC3339153
Buyyounouski MK. Androgen deprivation therapy in high-risk prostate cancer. Oncology (Williston Park). 2010 Aug;24(9):806, 809.   PMCID: Not NIH funded
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochemical pharmacology. 2010 Sep;80(5):762-70.   PMCID: PMC2897922
Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU international. 2010 Jul;106(2):218-23.   PMCID: PMC2906619
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.   PMCID: PMC 2668552
Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. European journal of pharmacology. 2009 Dec 25;625(1-3):41-54.   PMCID: PMC2783916
Fourkal E, Fan J, Veltchev I. Absolute dose reconstruction in proton therapy using PET imaging modality: feasibility study. Phys Med Biol. 2009 Jun 07;54(11):N217-28.
Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR. Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys. 2009 Jul;74(3):689-94.   PMCID: PMC2720600
Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast. 2009 Oct;18 Suppl 3:S10-7.   PMCID: PMC2867601
Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009 May;74(1):55-9.   PMCID: PMC2933375
Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009 May;115(9):1859-66.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use Female drug therapy Male pathology Middle Aged methods Aged Adult Antineoplastic Agents radiotherapy Antineoplastic Combined Chemotherapy Protocols Treatment Outcome therapy dosage 80 and over Aged administration & pharmacokinetics Combined Modality Therapy metabolism adverse effects Neoplasms Radiotherapy Dosage Neoplasm Staging surgery Disease-Free Survival analogs & Neoplasm Metastasis chemically induced Young Adult derivatives Positron-Emission Tomography mortality Urinary Bladder Neoplasms Retrospective Studies Breast Neoplasms Monte Carlo Method radionuclide imaging Deoxycytidine administration & dosage Mice Radiopharmaceuticals Radiation Dosage Head and Neck Neoplasms Monoclonal Antibodies Renal Cell Carcinoma Apoptosis Cystectomy Radioimmunotherapy Drug Delivery Systems Imaging Phantoms diagnostic use Prostatic Neoplasms Intensity-Modulated Radiotherapy Prospective Studies Epidermal Growth Factor Receptor Adenocarcinoma Kidney Neoplasms Fluorodeoxyglucose F18 immunology Androgen Antagonists Photons Adjuvant Chemotherapy Squamous Cell Carcinoma Immunotherapy Epidemiologic Methods Tamoxifen Breast Xenograft Model Antitumor Assays agonists Tissue Distribution Triazoles antagonists & Carboplatin Ovarian Neoplasms Intestinal Neoplasms Cyclooxygenase 2 Inhibitors Tetrahydronaphthalenes Esophageal Neoplasms Glioblastoma Segmental Mastectomy Lymph Node Excision Dendritic Cells Topotecan Angiogenesis Inhibitors Nitriles Immunoenzyme Techniques G-Protein-Coupled Receptors Maximum Tolerated Dose Antineoplastic Combined Chemotherapy Androgens Toll-Like Receptors Gastrostomy Benzhydryl Compounds Chemoradiotherapy Western Blotting antagonists & inhibitors Rats Disease Progression Survival Rate Multivariate Analysis Kidney Anticarcinogenic Agents Nephrectomy Cisplatin Pyrazoles Acute Disease Postmenopause Patient Selection Recurrence Inbred F344 Rats Local Neoplasm Recurrence Aromatase Inhibitors Radiodermatitis Aurora Kinases Hormone-Dependent Neoplasms Nonparametric Statistics Clinical Trials as Topic Gamma Rays Peritoneal Neoplasms Half-Life Proportional Hazards Models Dacarbazine utilization Animal Disease Models Water deficiency Signal Transduction histology Theoretical Models Nude Mice Protocols Follow-Up Studies Urothelium Paclitaxel Progesterone Receptors Disorders of Excessive Somnolence erbB-2 Receptor Treatment Failure Sprague-Dawley Rats Electrons genetics Lymphatic Metastasis Drug Carriers Non-Steroidal Anti-Inflammatory Agents drug effects Three-Dimensional Imaging Estradiol Analysis of Variance adverse
Last updated on Friday, January 03, 2020